NSEBSE
There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.Open-
High-
Low-
Prev. Close-
Avg. Traded Price-
Volume-
MARKET DEPTH
Total bid0.00
Total ask0.00
HIGH/LOW
LOW/HIGH
₹362.002 days ago
₹369.002 days ago
Fermenta Biotech an established enterprise with a rich seven-decade history, operates across diverse sectors, including pharmaceuticals, animal feed, nutrition, integrated biotech, environmental solutions and real estate. A key focal point of the company’s expertise lies in the comprehensive manufacturing of Vitamin D3. The Company maintains a sustainable supply chain, providing a notable advantage in the contemporary global market.The company’s array of Vitamin D3 variants is finely balanced to meet the requirements of both human and animal nutrition, rendering them applicable across a broad spectrum of uses. In addition to Vitamin D3 products, the company engages in the production of APIs for muscle relaxants and anti-flatulent applications. The Company also pioneers the development of innovative enzymes crucial for manufacturing active pharmaceutical ingredients, alongside offering environmental solutions for wastewater treatment and management.The strategic possession of legacy properties in Thane and Worli, Mumbai, serves as a lucrative source of income for the company. This supplementary revenue stream complements the core business activities, reinforcing the Company’s financial position. Through a development agreement with Mextech Property Developers LLP, the company is poised to construct residential-cum-commercial buildings on its free-hold Thane land and would acquire affordable luxury residential apartments from Mextech on an area sharing basis.Furthermore, the company has undertaken sale transactions for its IT/ITES building, Thane One. As of the report date, the company has successfully divested a significant portion of the IT/ITES building to third parties. The proceeds from these transactions were judiciously utilized to retire outstanding loans associated with the IT/ITES building.Business area of the companyThe company is engaged in the business of manufacturing and marketing of chemicals, bulk drugs, enzymes, pharmaceutical formulations and environmental solution products and renting and selling of properties. The Company caters to both domestic and international markets. The company also has strategic investments in subsidiaries primarily dealing in manufacturing and marketing bulk drugs.Business SegmentsVitamin D and niche APIsNutritionIntegrated biotechnologyEnvironment solutionsReal EstateAwards2025: Pride of Maharashtra Award2024: Fi India Awards2023: Excellence in Pharma Supply Chain Award2021: Indian Pharma Award2020: Business Leader of The Year Awards2020: Hindustan Times Thane Ratna Award2019: Business Excellence Awards2019: Hindustan Times Thane Ratna Award2018: Indian Pharma AwardMilestones/ History1951: Established International Franchises Private Ltd. to focus on the toll manufacturing of pharmaceutical products.1963: Formed joint venture with Philips Duphar SV1967: Commenced the commercial manufacture of Vitamin D1980: After Solvay acquired Philips Duphar SV, it became the new joint venture partner.1986: Established the company to manufacture enzymes used as catalyst in antibiotic manufacturing.2002: Demerged the pharmaceutical business to Solvay.2003: Consolidated all manufacturing at kullu by expanding the facility to include Vitamin D and other products.2011: Commenced the second plant for manufacturing Vitamin D at Dahej.2012: The company introduced its latest catalyst Fermase PA 850 for Penicillin G Acylase and enhanced the production capacity of Vitamin D resin in Dahej.2014: Launched Vitamin D 100 CWD to cater to the food and dietary nutraceutical supplements market.2016: Enhanced Vitamin D capacity at Dahej. Launched a new version of Vitamin D 500 feed grade powder.2017: Obtained EDQM’s CEP certification for its Vitamin D manufacturing facility in Dahej; and received FSSC 22000 and BRC food safety approvals for both plants.2019: Completed the amalgamation of DIL Limited and Fermenta Biotech Limited (combined entity was renamed as Fermenta Biotech Limited). Incorporated a wholly owned subsidiary called Fermenta Biotech GmbH in Germany. Integrated backwards to manufacture cholesterol, the key starting material of Vitamin D.2020: Introduced fish oil cholesterol for aquaculture nutrition. Established a wholly owned subsidiary named Fermenta Biotech USA LLC in the USA. Acquired a controlling stake in AGD Nutrition, a US-based vitamin company, through Fermenta Biotech USA LLC and renamed it as Fermenta USA LLC.2021: Launched Vitamin AD2 for oil fortification.2022: Signed a binding term sheet with Mextech Property Developers LLP for the development of a land parcel in Thane. Fermenta commissioned its fortified rice kernel manufacturing facility in Pennepalli, Andhra Pradesh.2023: Commissioned its customised food premixing plant in Kullu, Himachal Pradesh.
